Company News: Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
– Dr. Nils Clausnitzer elected as member of the Supervisory Board
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual Shareholder Meeting (“AGM”) held in Amsterdam on June 23, 2017.
Company News: Agena Bioscience Announces Expanded Partnership with Assurex Health
– MassArray® System Selected for Assurex Health’s GeneSight Test
Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test.
Company News: Nature Medicine reports elimination of large tumors in mice by messenger RNA-encoded bispecific antibodies
– Novel mRNA-based antibody drug class holds promise for fast development of potent immunotherapies
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported preclinical data featuring a novel class of mRNA-encoded antibody drugs called RiboMABs®. In Nature Medicine, BioNTech presents the application of this technology for mRNA-based in vivo delivery of T cell engaging bispecific antibodies. The study entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” can be found here: http://nature.com/articles/doi:10.1038/nm.4356.
